NCT03299426: Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi |
|
|
| Active, not recruiting | 3 | 30000 | RoW | Vi-Typhoid Conjugate Vaccine (Vi-TCV), Meningococcal A Conjugate Vaccine (MCV-A) | University of Maryland, Baltimore, Bill and Melinda Gates Foundation, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University College, London, University of Malawi | Typhoid | 10/24 | 10/25 | | |
NCT05480800 / 2021-005178-25: A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever |
|
|
| Recruiting | 1/2 | 155 | Europe, RoW | Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose, Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose, Typhoid conjugate vaccine (TCV) low dose, Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full dose, Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full dose, Typhoid conjugate vaccine (TCV) full dose, GSK's Meningococcal A, C, Y and W-135 conjugate vaccine, MENVEO, GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, Boostrix, Sanofi Pasteur's Typhoid Vi polysaccharide vaccine, TYPHIM Vi, Placebo, Saline | GlaxoSmithKline, Biomedical Advanced Research and Development Authority, Wellcome Trust, Global Antimicrobial Resistance Innovation Fund-(GAMRIF), Bill and Melinda Gates Foundation | Salmonella Infections | 12/24 | 12/24 | | |
